The value of an artificial neural network in the decision-making for prostate biopsies
Tóm tắt
In majority of patients who are subjected to prostate biopsies, no prostate cancer (PCa) is found. It is important to prevent unnecessary biopsies since serious complications may occur. An artificial neural network (ANN) may be able to predict the risk of the presence of PCa. Included were all patients, who underwent transrectal ultrasound-guided prostate biopsies between June 2006 and June 2007 with a total PSA (tPSA) level between 2 and 20 μg/l. The patients were divided into two groups according to their tPSA level (2–10 μg/l and 10–20 μg/l). The ANN Prostataclass of the Universitätsklinikum Charité in Berlin was used. The predictions of the ANN were compared to the pathology results of the biopsies. Overall 165 patients were included. PCa was diagnosed in 53 patients, whereas the ANN predicted “no risk” in 19 of these patients (36%). The ANN output receiver operator characteristic (ROC) plots for the range of tPSA 2–10 μg/l and tPSA 10–20 μg/l showed an area under the curve (AUC) of 63 and 88% for the initial biopsy group, versus 69 and 57%, respectively, for the repeat biopsy group. The ANN resulted in a false negative rate of 36%, missing PCa in 19 patients. For use in an outpatient-clinical setting, this ANN is insufficient to predict the risk of presence of PCa reliably.
Tài liệu tham khảo
Partin AW, Oesterling JE (1994) The clinical usefulness of prostate specific antigen: update 1994. J Urol 152:1358–1368
Polascik TJ, Oesterling JE, Partin AW (1999) Prostate specific antigen: a decade of discovery–what we have learned and where we are going. J Urol 162:293–306
Beduschi MC, Oesterling JE (1997) Prostate-specific antigen density. Urol Clin North Am 24:323–332
Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547
Carter HB, Pearson JD (1997) Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 24:333–338
Nixon RG, Brawer MK (1997) Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br J Urol 79(Suppl 1):61–67
Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS (2006) A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67:762–768
Okihara K, Cheli CD, Partin AW, Fritche HA, Chan DW, Sokoll LJ et al (2002) Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol 167:2017–2023
Gann PH, Ma J, Catalona WJ, Stampfer MJ (2002) Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 167:2427–2434
Stephan C, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G et al (2002) An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation. Int J Cancer 99:466–473
Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A et al (2004) The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population. Jpn J Clin Oncol 34:602–607
Virtanen A, Gomari M, Kranse R, Stenman UH (1999) Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45:987–994
Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A et al (2004) Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111:310–315
Remzi M, Anagnostou T, Ravery V, Zlotta AR, Stephan C, Marberger M et al (2003) An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 62:456–460
Stephan C, Cammann H, Meyer HA, Lein M, Jung K (2007) PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 249:18–29
Montie JE, Wei JT (2000) Artificial neural networks for prostate carcinoma risk assessment: an overview. Cancer 88:2655–2660
Chun FK, Graefen M, Briganti A, Gallina A, Hopp J, Kattan MW et al (2007) Initial biopsy outcome prediction—head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 51:1236–1240
Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K et al (2008) Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 54:601–611
Wei JT, Zhang Z, Barnhill SD, Madyastha KR, Zhang H, Oesterling JE (1998) Understanding artificial neural networks and exploring their potential applications for the practicing urologist. Urology 52:161–172
Dayhoff JE, DeLeo JM (2001) Artificial neural networks: opening the black box. Cancer 91:1615–1635
Anagnostou T, Remzi M, Djavan B (2003) Artificial neural networks for decision-making in urologic oncology. Rev Urol 5:15–21
Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M et al (2002) Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48:1279–1287
Djavan B, Remzi M, Zlotta AR, Seitz C, Snow P, Marberger M (2002) Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20:921–929
Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B (2003) An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng/ml or less. J Urol 169:1724–1728
Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W et al (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56:1000–1006